Jun13698 

Jun13698 is a SARS-CoV-2 main protease (M^pro) inhibitor with K_i values of 65.6 nM, 510.0 nM, and 117.5 nM against the wild-type, E166V, and E166A mutants, respectively. Jun13698 forms stable complexes with wild-type and mutant M^pro to mediate enzyme inhibition. Jun13698 exhibits antiviral activity against SARS-CoV-2 variants carrying the E166V/A mutation. Jun13698 is applicable to COVID-19-related research^[1].

Jun13698 potently inhibits wild-type and Nirmatrelvir (HY-138687)-resistant recombinant SARS-CoV-2 in Vero E6 cells, with an rWT EC₅₀ of 0.08 μM and EC₅₀ values ranging from 0.20 μM to 1.01 μM against the mutant strains. It shows no cytotoxicity even at concentrations as high as 250 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

465.53

C₂₀H₃₀F₃N₃O₄S

O=C([C@@H]1[C@@]2([H])C(C)(C)[C@@]2([H])CN1C([C@H](C(C)C)NC(C(F)(F)F)=O)=O)N[C@@H](CCSC)C=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Cai Z, et al. Structure-Based Design of Covalent SARS-CoV‑2 Main Protease Inhibitors Targeting the Nirmatrelvir-Resistant E166 Mutants. JACS Au. 2026;6(1):233-244. Published 2026 Jan 12.  [Content Brief]